Menopause timing, hormone therapy, epigenetic aging, and breast cancer outcomes: a secondary analysis of the PLCO Cancer Screening Trial
Background: Current recommendations limit the use of menopausal hormone therapy (MHT) principally to the management of menopausal symptoms, largely because of concerns regarding increased breast cancer (BC) risk. The impact of MHT use on systemic biological aging and blood methylome and its overlap with that of menopau...